SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

NCT06927180 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

180

Enrollment

OTHER_GOV

Sponsor class

Conditions

Breast Cancer Early Stage Breast Cancer (Stage 1-3)

Interventions

DRUG: SHR-A1811
DRUG: Pertuzumab
DRUG: Albumin-Paclitaxel
DRUG: Docetaxel
DRUG: Carboplatin
DRUG: Trastuzumab

Sponsor

Henan Cancer Hospital